Ultrasound-induced microbubble cavitation via a transcanal or transcranial approach facilitates inner ear drug delivery

JCI Insight. 2020 Feb 13;5(3):e132880. doi: 10.1172/jci.insight.132880.

Abstract

Ultrasound-induced microbubble (USMB) cavitation is widely used to promote drug delivery. Our previous study investigated USMB targeting the round window membrane by applying the ultrasound transducer to the tympanic bulla. In the present study, we further extended the use of this technology to enhance drug delivery to the inner ear by introducing the ultrasound transducer into the external auditory canal (EAC) or applying it to the skull. Using a 3-dimensional-printed diffusion apparatus mimicking the pathway for ultrasound passing through and reaching the middle ear cavity in vitro, the models simulating the transcanal and transcranial approach demonstrated 4.8-fold- and 3.7-fold-higher delivery efficiencies, respectively. In an in vivo model of guinea pigs, by filling tympanic bulla with microbubbles and biotin-FITC, USMB applied transcanally and transcranially induced 2.8-fold and 1.5-fold increases in biotin-FITC delivery efficiencies, respectively. In addition, the gentamicin uptake by cochlear and vestibular hair cells and gentamicin-induced hair cell loss were significantly enhanced following transcanal application of USMB. On the 28th day after transcanal USMB, safety assessment showed no significant changes in the hearing thresholds and the integrity of cochlea. These are the first results to our knowledge to demonstrate the feasibility and support the potential clinical application of applying USMB via EAC to facilitate drug delivery into the inner ear.

Keywords: Nanotechnology; Otology; Pharmacology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / administration & dosage*
  • Drug Delivery Systems / methods*
  • Ear, Inner / metabolism*
  • Gentamicins / administration & dosage*
  • Guinea Pigs
  • Microbubbles*
  • Sonication*

Substances

  • Anti-Bacterial Agents
  • Gentamicins

Grants and funding

MOST106-2221-E-011-043-MY3 to Ai-Ho Liao, MOST107-2314-B-663-001-MY3 to Chih-Hung Wang, and MOST107-2314-B-016-027 and MOST108-2314-B-016-038 to Cheng-Ping Shih